Key result
Systematic screening for asymptomatic coronary artery disease in patients with diabetes mellitus did not significantly reduce all-cause death (OR 1.00) compared to no screening.
Why the study?
Does systematic screening for asymptomatic coronary artery disease reduce mortality or myocardial infarction in patients with diabetes mellitus?
Meta-Analysis (n=3,314)
Yes
Does systematic screening for asymptomatic coronary artery disease reduce mortality or myocardial infarction in patients with diabetes mellitus?
Effect estimate: OR 1.00 (95% CI 0.67-1.50)
p-value: p=0.996
Routine screening for asymptomatic coronary artery disease in diabetic patients does not significantly reduce mortality or non-fatal myocardial infarction and leads to low rates of revascularization.
Does not support routine screening for asymptomatic CAD in diabetes; confirms no mortality benefit and low revascularization rates.
BACKGROUND: Screening diabetic patients for the presence of asymptomatic coronary artery disease (CAD) may potentially impact therapeutic management and outcome. We performed a systematic review and meta-analysis of randomized trials addressing this question. METHODS: We searched the PubMed database for studies reporting a randomized comparison of systematic screening for CAD in diabetic patients versus no systematic screening. The screening protocols were variable with the use of exercise electrocardiogram test, or stress echocardiography, or nuclear test, or coronary computed tomography angiography. RESULTS: The final analysis included 5 randomized studies and 3,314 patients altogether. The screening strategy had no detectable impact on outcome with odds ratios (OR) [95 % confidence interval (CI)] of 1.00 [0.67-1.50], 0.72 [0.33-1.57], 0.71 [0.40-1.27], and 0.60 [0.23-1.52] for all-cause death, cardiovascular death, non-fatal myocardial infarction, and the composite cardiovascular death or non-fatal myocardial infarction, respectively. Protocol-related coronary procedures were relatively infrequent in screened patients: coronary angiography was performed in 8 % of the cases, percutaneous coronary intervention in 2.5 %, and coronary artery bypass surgery in 1.5 %. There was no evidence for an effect of screening on the use of statins (OR = 1.19 [0.94-1.51]), aspirin (OR = 1.02 [0.83-1.25]), or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (OR = 0.97 [0.79-1.19]). CONCLUSION: The present analysis shows no evidence for a benefit of screening diabetic patients for the presence of asymptomatic CAD. The proportion of patients who undergo myocardial revascularization as a consequence of screening was low.
No takes yet. Share an insight, caveat, or question.
Bauters et al. (2016) conducted a meta-analysis in Asymptomatic coronary artery disease in diabetes mellitus (n=3,314). Systematic screening for coronary artery disease vs. No systematic screening was evaluated on All-cause death (OR 1.00, 95% CI 0.67-1.50, p=0.996). Systematic screening for asymptomatic coronary artery disease in patients with diabetes mellitus did not significantly reduce all-cause death (OR 1.00) compared to no screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: